Encontrados 4 documentos, a visualizar página 1 de 1
Allogeneic stem cell transplantation in patients with myelodysplastic syndrome:...
Rubio, S; Martins, C; Lacerda, J F; Carmo, J A; Lourenço, F; Lacerda, J M FWe determined the outcome of patients with myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia (sAML) after allogeneic stem cell transplantation according to their international prognostic scoring system (IPSS) risk categories at diagnosis. A total of 11 females and 7 males, with a median age of 45 years, were transplanted. With a median follow-up of 60 months, the 6-year actuarial event-free su...
Donor leukocyte infusion after allogeneic stem cell transplantation.
de Lacerda, J F; Unidade de Hematologia, Hospital de Santa Maria, Lisboa.Adoptive cellular immunotherapy with donor leukocytes of patients submitted to allogenic stem cell transplantation has had significant success in the past few years, especially in the treatment of primary disease relapse and in the prevention and treatment of some post-transplant infectious complications. Most patients treated with donor leukocytes had a relapse of chronic myelogenous leukemia, which was succes...
Treatment of acute promyelocytic leukemia with trans-retinoic acid. Experience ...
De Lacerda, J F; Unidade de Hematologia, Universidad de Lisboa, Hospital de Santa Maria, Faculdade de Medicina de Lisboa.; Do Carmo, J A; De Moura, M CAcute promyelocytic leukemia (APL) is a rare subtype of acute myelogenous leukemia that is usually associated with a fatal hemorrhagic diathesis. All trans-retinoic acid (ATRA) is an active metabolite of vitamin A that differentiates the malignant cell clone, corrects the coagulopathy, and induces complete remission in the vast majority of patients with APL. Between June 1992 and September 1993, 8 patients with...
Acute promyelocytic leukemia. The therapeutic advances.
de Lacerda, J F; Unidade de Hematologia, Hospital de Santa Maria, Faculdade de Medicina de Lisboa.; do Carmo, J A; de Lacerda, J MAcute promyelocytic leukemia (APL) is a rare subtype of acute myelogenous leukemia. It is frequently associated with a life-threatening hemorrhagic diathesis, often aggravated by induction cytotoxic chemotherapy. Patients with APL have bone marrow infiltration by abnormal promyelocytes, usually with prominent cytoplasmic granulation. These patients have a unique cytogenetic abnormality, a balanced reciprocal tr...
| Financiadores do RCAAP | |||||||
|
|
|
|
|
|
||